ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Leerink Swann 2012 Global Healthcare Conference on February 16, 2012 at 11:00 a.m.. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule's lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company's pipeline consists of ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736, designed to inhibit the RAF kinases. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
Contacts:
ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor
Relations/
Corp. Communications
www.ArQule.com
